Does APIXABAN Cause Hepatic steatosis? 56 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 56 reports of Hepatic steatosis have been filed in association with APIXABAN (ELIQUIS). This represents 0.0% of all adverse event reports for APIXABAN.
56
Reports of Hepatic steatosis with APIXABAN
0.0%
of all APIXABAN reports
0
Deaths
35
Hospitalizations
How Dangerous Is Hepatic steatosis From APIXABAN?
Of the 56 reports, 35 (62.5%) required hospitalization, and 1 (1.8%) were considered life-threatening.
Is Hepatic steatosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APIXABAN. However, 56 reports have been filed with the FAERS database.
What Other Side Effects Does APIXABAN Cause?
Death (18,501)
Cerebrovascular accident (7,237)
Atrial fibrillation (5,690)
Off label use (5,590)
Thrombosis (5,298)
Fall (5,063)
Cardiac disorder (4,917)
Haemorrhage (4,770)
Dyspnoea (4,379)
Gastrointestinal haemorrhage (4,030)
What Other Drugs Cause Hepatic steatosis?
METHOTREXATE (1,400)
ADALIMUMAB (1,058)
ETANERCEPT (620)
TOCILIZUMAB (476)
TOFACITINIB (405)
LEFLUNOMIDE (359)
HYDROXYCHLOROQUINE (358)
ABATACEPT (345)
METFORMIN (343)
INFLIXIMAB (325)
Which APIXABAN Alternatives Have Lower Hepatic steatosis Risk?
APIXABAN vs APOMORPHINE
APIXABAN vs APRACLONIDINE
APIXABAN vs APREMILAST
APIXABAN vs APREPITANT
APIXABAN vs APROTININ